**中国专家最新研究成果大幅提升头颈部原发不明肿瘤原发灶诊断准确率**
**上海，1月27日**——头颈部原发不明肿瘤是一组高度异质性的恶性肿瘤，现有的临床检查方法均无法明确原发灶来源。中国医学专家团队尝试用新型分子影像来定位原发肿瘤部位，将原发灶诊断准确率从19%提高到51%。
这项研究由复旦大学附属肿瘤医院、上海交通大学医学院附属第九人民医院、中国医学科学院肿瘤医院、北京大学肿瘤医院、中国医学科学院北京协和医学院等单位的专家共同完成。研究成果发表在国际知名医学期刊《柳叶刀·肿瘤学》上。
研究团队对108例头颈部原发不明肿瘤患者进行了新型分子影像检查，并与传统的临床检查方法进行了比较。结果发现，新型分子影像检查的原发灶诊断准确率为51%，而传统的临床检查方法的原发灶诊断准确率仅为19%。
研究团队认为，新型分子影像检查可以帮助医生更准确地诊断头颈部原发不明肿瘤的原发灶来源，从而为患者提供更有效的治疗。
头颈部原发不明肿瘤是一种罕见的癌症，每年约有10万人被诊断出患有这种疾病。这种癌症的预后通常较差，5年生存率仅为30%左右。
研究团队表示，新型分子影像检查可以帮助医生更准确地诊断头颈部原发不明肿瘤的原发灶来源，从而为患者提供更有效的治疗。他们希望这项研究成果能够帮助提高头颈部原发不明肿瘤患者的生存率。
英语如下：
Headline: Molecular Imaging Technique Aids in Primary Tumor Localization of Head and Neck Cancersof Unknown Origin
Keywords: Tumor localization, molecular imaging, diagnostic accuracy
Article Content:
**Shanghai, January 27**—Head and neck cancersof unknown primary (CUP) are a group of highly heterogeneous malignancies for which current clinical workup fails to identify the primary tumor site. A team of Chinese medical experts has attempted to use a novel molecular imaging approach to localize the primary tumor site, increasing the diagnostic accuracy from 19% to 51%.
The study was conducted by experts from Fudan University附属肿瘤医院, the Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital, and Peking Union Medical College, Chinese Academy of Medical Sciences. The findings were published in the international medical journal, The Lancet Oncology.
The research team conducted novel molecular imaging examinations on 108 patients with head and neck CUP and compared the results with those obtained using conventional clinical examination methods. The results showed that the novel molecular imaging examination had a primary tumor diagnostic accuracy of 51%, while the conventional clinicalexamination methods had a primary tumor diagnostic accuracy of only 19%.
The research team believes that the novel molecular imaging examination can help doctors more accurately diagnose the primary tumor site of head and neck CUP, thereby providing patients with more effective treatment.
Head and neck CUP is a rare cancer, with approximately 100,000 people diagnosed with the disease each year. The prognosis of this cancer is generally poor, with a 5-year survival rate of only around 30%.
The research team stated that the novel molecular imaging examination can help doctors more accurately diagnose the primary tumor site of head and neck CUP, thereby providing patients with more effective treatment. They hope that the findings of this study will help improve the survival rate of patients with head and neck CUP.
【来源】http://www.chinanews.com/life/2024/01-27/10154071.shtml
Views: 1